Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list Implications for donor selection criteria by Lietz, Katherine et al.
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utcomes in Cardiac Transplant
ecipients Using Allografts From Older Donors
ersus Mortality on the Transplant Waiting List
mplications for Donor Selection Criteria
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OBJECTIVES This study investigates the outcomes of cardiac transplantation using older donors.
BACKGROUND Despite high mortality rates on waiting lists, transplanting hearts from older donors remains
a relative contraindication.
METHODS We retrospectively reviewed data on 479 adult heart transplant recipients, 352 status I
patients, and 534 status II patients enrolled on a waiting list between 1992 and 1999. The
Cox proportional hazards model was used for statistical analysis.
RESULTS Of all donors, 20% were 40 to 50 years old and 8% were50 years old. The risk of six-month
mortality on the waiting list for patients who were not transplanted (status I: relative risk
[RR] 8.5; status II: RR 3.7) significantly outweighed the risk of transplanting patients with
a heart from donors 40 years old (status I: RR 1.6; status II: RR 2.1). Recipients of cardiac
allografts from donors 40 years old had a one-month mortality rate of 5%, in contrast to
13% and 22% in those receiving allografts from donors 40 to 50 years old and 50 years old,
respectively. Donor age did not influence long-term survival or frequency of rejections;
however, it did correlate with the early presence of transplant-related coronary artery disease
(TCAD). By the first annual angiogram, only 17% of recipients with donors 20 years old
developed TCAD, in contrast to 26% to 30% and 34% of recipients who received allografts
from donors age 20 to 40 years and 40 years, respectively.
CONCLUSIONS Despite a strong association between older donor age and increased post-operative mortality
and TCAD, it is more beneficial in terms of patient survival to receive an allograft from a
donor 40 years old than to remain on the waiting list. (J Am Coll Cardiol 2004;43:
1553–61) © 2004 by the American College of Cardiology Foundationp
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ng demand for cardiac transplantation has led to the
xpansion of donor acceptance criteria, particularly with
espect to donor age. Early in the experience of heart
ransplantation, the upper limit of donor age was 35 years
1). Major concerns about older donors were related to a
reater susceptibility of early irreversible graft failure (2) and
See page 1562
he transmission of coronary artery disease (CAD), hyper-
ensive heart disease, or valvular degeneration from the
onor heart (3). However, despite these concerns, as a result
f an increased demand for cardiac transplantation and a
ecreasing donor pool, older donors are used with increasing
requency. According to the International Heart and Lung
ransplantation Registry, the mean age of heart donors rose
rom 23 years in 1985 to 30 years between 1991 and 1996,
ith a slight decline to 27.5 years in 1999 (4).
From the Division of *Cardiothoracic Surgery and †Cardiology, Columbia Pres-
yterian Medical Center, Columbia University, New York, New York.
Manuscript received June 6, 2003; revised manuscript received August 9, 2003,tccepted August 18, 2003.The effect of liberalization of donor selection criteria on
ost-transplant recipient outcomes has been questioned.
any single-center analyses report that the use of older
onor hearts has not affected post-transplant survival (5–
3). However, large multi-institutional studies (14,15) and
he International Heart and Lung Transplantation Registry
4) reported increased mortality in heart transplant recipi-
nts receiving older donor hearts. Discrepancies between
revious single-center studies and results from large cohort
nalyses are probably related to a smaller number of patients
nd short observation times at individual institutions (16).
he objective of this study was to investigate post-
ransplant outcomes in recipients of older donor hearts in a
arge-volume, single-center study. This current study pro-
ides adequate statistical power and follow-up periods and,
ore importantly, was performed during an era in which all
ecipients received standard triple immunosuppressive ther-
py. Furthermore, in order to study the risk/benefit ratio in
atients receiving older donor hearts, we also compared
ost-transplant survival data in recipients who received
lder donor hearts with waiting list mortality for patients
ith end-stage heart failure awaiting cardiac transplanta-ion.
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atients. Between January 1992 and January 1999, 479
ransplantations (448 primary and 31 re-transplants) were
erformed on adult recipients (age 18 years) at the
olumbia Presbyterian Medical Center in New York City.
he patients were predominantly male (78.1%) and Cauca-
ian (79.5%), with a mean age of 50.1  13.2 years. The
ajority of donors were male (60%) and Caucasian (80%),
ith a mean age of 31.6  13.2 years. The major cause of
eath was head trauma (40%) and cerebrovascular accident
CVA) (38%), followed by anoxia (6%) and other causes
16%). The mean donor ischemia time was 173  60 min.
complete mismatch at human leukocyte antigen (HLA)
oci was present in HLA-A in 62%, HLA-B in 79%, and
LA-DR in 66% of patients. Of the 479 patients, between
anuary 1992 and January 1999, 453 were enrolled by
nited Network of Organ Sharing (UNOS) on a waiting
ist: 187 (39%) as status I and 266 (61%) as status II. The
ean waiting time to transplantation for patients enrolled as
tatus I and status II was 4.1 and 13.4 months, respectively.
he mean waiting times to surgery in consecutive eras of
ransplantation (i.e., 1992 to 1993, 1994 to 1996, and 1997
o 1999) were 1.6, 4.6, and 4.6 months for status I patients
nd 22.8, 13.6, and 14.1 months for status II patients,
espectively. The UNOS data on the enrollment status for
6 patients transplanted before 1992 were not available. The
ne- and five-year patient survival rates were 80.9% and
6.9%, respectively, with a mean follow-up of 3.13  2.26
ears (range 0 to 8 years).
In addition, we evaluated the survival of 352 status I and
34 status II patients at Columbia Presbyterian Medical
enter enrolled on the UNOS waiting list for primary heart
ransplantation between January 1992 and January 1999.
orty-five patients who were moved to another center while
n the waiting list, transplanted at another center, or who
eceived multiple organ transplants were excluded from the
nalysis. Of these 886 patients, 231 (26%) died while on
aiting list and 172 (19%) were still awaiting transplanta-
ion.
Before undergoing heart transplantation, a left ventricular
ssist device (LVAD) was used in 125 patients, of whom 93
ere successfully transplanted, 29 died after device inser-
ion, and three were still awaiting transplantation at the
ime of analysis.
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
CVA  cerebrovascular accident
HLA  human leukocyte antigen
LVAD  left ventricular assist device
RR  relative risk
TCAD  transplant-related coronary artery disease
UNOS  United Network of Organ Sharinglinical data. The following pre-transplant variables were
nalyzed: recipient age, gender, ethnicity, pre-transplant
iagnosis, donor age, gender, ethnicity, complete mismatch
t HLA-A, -B, and -DR loci, pre-transplant LVAD
upport, and UNOS status at listing. Post-transplant data
n acute rejection, transplant-related coronary artery disease
TCAD), and survival were evaluated.
perative techniques. Donor hearts were harvested from
eating-heart, brain-dead individuals. Graft procurement
nd preservation employed cold cardioplegic arrest using the
niversity of Wisconsin solution and topical hypothermia.
rom 1992 to 1996, orthotopic cardiac transplantation was
erformed using the biatrial technique described by Lower
nd Shumway (17). Since 1996, we have performed almost
ll transplants using the bicaval anastomosis technique (17).
mmunosuppressive regimen. All patients received triple
mmunosuppression, consisting of cyclosporine, steroids,
nd azathioprine. Azathioprine was given at an initial
re-operative dose of 4 mg/kg/day, followed by a daily
ntravenous dose of 2 mg/kg until the patient could tolerate
ral medication. Since 1996, azathioprine has been replaced
y mycophenolate mofetil, starting at a dose of 1,000 mg
wice daily. Cyclosporine was given at the initial dose of 1 to
mg/kg/day and adjusted to maintain trough whole-blood
evels between 300 and 350 ng/dl. Between three and six
onths after transplantation, the cyclosporine dosage was
djusted to maintain blood levels between 150 and 250
g/dl, and after six months, between 100 and 150 ng/dl.
ntravenous methylprednisolone (500 mg) was administered
uring the operation and in the postoperative period at a
ose of 125 mg every 8 h over 24 h. Prednisone was given
n tapering doses of 1 mg/kg per day immediately post-
peratively to 0.1 mg/kg/day by the fourth month. Rejec-
ion episodes were treated with oral or intravenous pulses of
teroid 100 mg/day for three days, followed by a taper over
ne week to the baseline dose. Non-responders to steroid
herapy were treated with cytolytic therapy.
cute rejection. Rejection was diagnosed by routine endo-
yocardial biopsy—weekly for the first 4 weeks, then every
weeks for the next 1 month, monthly for 4 months, then
very 2 months for the next 6 months, followed by every 3
onths for the next 6 months, and then every 6 to 12
onths. The biopsy fragments were graded according to
nternational Society for Heart and Lung Transplantation
ISHLT) criteria (18). High-grade cellular allograft rejec-
ion was defined pathologically as grade 3A or 3B.
ngiography/diagnosis of TCAD. The diagnosis of
CAD was based on the following: 1) discrete lesions
esulting in 50% obstruction of the proximal or mid-
ortions of major graft vessels; or 2) diffuse, concentric
arrowing of the whole vessels, including their branches. If
CAD was identified, the frequency of angiography was
ncreased to a biannual regimen. Patients were not given
outine vasodilators before coronary injections. In patients
ith possible diffuse CAD, the intimal thickening was
ocumented by vascular ultrasound. All coronary angio-
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he previous year’s films to detect the presence of luminal
rregularities, discrete stenoses, loss of third-order branches,
r pruning of vessels. Hearts explanted before retransplan-
ation and postmortem heart autopsy specimens were ex-
mined for evidence of vessel occlusion and irregularities,
schemic damage, and the presence of acute cardiac
ejection.
LA typing. Serologic typing of HLA-A and -B loci was
erformed by standard microcytotoxicity techniques. HLA-
R typing was performed by serologic analysis.
tatistical analysis. Differences between groups were ex-
mined using the chi-square or Fisher exact test, if the
umber of expected frequencies in the examined group was
ess than five. The graphic distribution of recipient age in
able 1 was normal, and thus the Student t test was used to
ompare groups. Survival estimates were based on the
aplan-Meier method, and curves were compared using a
og-rank test (19). Univariate and multivariate analyses were
erformed to determine the independent impact of donor
ge on survival, the incidence of acute rejection episodes,
nd TCAD. All covariates listed in Table 2 were entered in
he multivariate Cox proportional hazards model using
tepwise selection. A subsequent multicollinearity analysis
evealed a maximal variance inflation factor of 1.9 (mean
.34). Hence, the parameter estimates have not been unduly
nfluenced by collinearity between predictors in the multi-
ariate analysis model. Results were considered significant at
Table 1. Comparative Statistics Between Youn
Donors <4
(n  3
Donor female gender 103 (30
Donor non-Caucasian ethnicity 74 (21
Donor cause of death
Head trauma 169 (49
CVA 85 (24
Anoxia 21 (6%
Other causes (unspecified) 71 (21
Donor CMV 174 (50
Mean (SD) recipient age (yrs) 49.2  1
Recipient non-Caucasian ethnicity 76 (22
Recipient female gender 86 (25
Recipient heart diagnosis
CAD 189 (55
ICM 100 (29
UNOS listed as status I* 127/293 (
LVAD support before Tx 68 (20
Retransplantation 26 (8%
Ischemic time 240 min 40 (12
Complete mismatch at
HLA-A locus 126 (38
HLA-B locus 65 (19
HLA-DR locus 111 (33
*Patients enrolled on UNOS waiting list between January 19
CAD  coronary artery disease; CMV  cytomegalo
lymphocyte antigen; ICM  idiopathic cardiomyopathy; LV
 United Network of Organ Sharing. 0.05. Data are reported as the mean value  SD. Data 0ere analyzed using the SAS System software, version 7.0
SAS Institute Inc., Cary, North Carolina).
ESULTS
onor age. The mean donor age in this study population
as 31.6 13.2 years (range 5 to 66 years). As illustrated in
able 3, the mean age of heart donors rose, from 29 years
uring the period from 1992 to 1993, to 33 years during the
994 to 1996 period, and it declined to 31 years from 1997
o 1999. The increase in mean donor age was related to a
elative increase in the percentage of donors 40 years old.
etween 1992 and 1993, only 20% of hearts from donors
lder than 40 years were accepted for transplantation, as
ompared with 32% after 1993 and 29% after 1997.
lder donor demographic data. As shown in Table 1, 74
56%) of 133 donors 40 years were females, in contrast to
nly 103 (30%) of 346 donors 40 years (p  0.001). The
ajor cause of death in the older donor population was
VA (74%), followed by head trauma (16%). Among
onors younger than 40 years, the causes of death included
ead trauma (49%), followed by CVA (24%). Donor eth-
icity, ischemic times, complete mismatch at HLA-A, -B,
nd -DR loci were similar across the donor age groups.
emographic data of recipients of allografts from older
onors. More allografts from older donors (40 years old)
ere transplanted into males than females; 114 (86%) of
33 older donors were transplanted into male recipients, as
ompared with 260 (75%) of 346 younger donors (p 
nd Older Heart Donors
rs Donors >40 Years
(n  133)
p Value by
Chi-Square Test
74 (56%)  0.0001
22 (16%) 0.23
21 (16%)  0.0001
98 (74%)  0.0001
7 (5%) 0.74
7 (5%)  0.0001
76 (57%) 0.18
53.1  10 0.007†
22 (16%) 0.19
19 (14%) 0.01
84 (63%) 0.09
35 (26%) 0.57
50/119 (42%) 0.80
22 (17%) 0.43
5 (4%) 0.13
12 (9%) 0.42
51 (40%) 0.67
30 (23%) 0.34
46 (37%) 0.44
d January 1999. †Student t test.
ositive; CVA  cerebrovascular accident; HLA  human
left ventricular assist device; Tx  transplantation; UNOSger a
0 Yea
46)
%)
%)
%)
%)
)
%)
%)
4
%)
%)
%)
%)
43%)
%)
)
%)
%)
%)
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Outcomes of Cardiac Transplantation From Older Donors May 5, 2004:1553–61onors was 53 years, as compared with a mean age of 49
ears in recipients receiving hearts from donors 40 years
ld (p  0.007). There were no differences in the demo-
raphic data of recipients who received hearts from older
ersus younger donors with respect to recipient ethnicity,
isting status, retransplantation, and LVAD implantation
efore transplantation.
nfluence of donor age on recipient survival after heart
ransplantation. As seen in Figure 1, older donor age (40
ears) adversely influences survival after heart transplanta-
ion. The 30-day post-transplant mortality rate in recipients
f hearts from donors 40 years old was 5% (19 of 346), in
ontrast to 13% (13 of 97) and 22% (8 of 36) in patients who
eceived hearts from donors whose age was between 40 and
0 years and50 years, respectively (p 0.004). Compared
ith donors 40 years old, the risk of early post-operative
able 2. Multivariate Analysis for Risk Factors of Postoperative
eath
Risk Factors RR (95% CI) p Value
ra of transplantation
1997–1999 1.0
1994–1996 2.691 (1.082–6.696) 0.033
1992–1993 5.136 (2.053–12.847)  0.001
etransplantation 0.363 (0.050–2.640) 0.32
onor age (yrs)
40 1.0
40–50 1.602 (0.690–3.721) 0.27
50 2.755 (1.153–6.579) 0.02
onor female gender 1.181 (0.572–2.437) 0.65
onor non-Caucasian ethnicity 0.832 (0.368–1.880) 0.66
onor cause of death
Head trauma 1.0
CVA 3.72 (0.214–2.719) 0.006
schemic time 4 h 2.473 (1.023–5.979) 0.04
omplete mismatch at
HLA-A locus 1.708 (0.818–3.569) 0.15
HLA-B locus 0.572 (0.280–1.169) 0.13
HLA-DR locus 0.947 (0.541–2.682) 0.95
ecipient age (yrs)
40–60 1.828 (0.784–4.260) 0.16
60 1.869 (0.711–4.911) 0.20
ecipient female gender 1.360 (0.679–2.722) 0.38
ecipient non-Caucasian ethnicity 1.117 (0.459–2.219) 0.81
VAD support before Tx 0.465 (0.166–1.307) 0.15
ecipient diagnosis of heart disease
CAD 0.905 (0.447–1.832) 0.78
ICM 1.491 (0.653–3.406) 0.34
I  confidence interval; RR  relative risk; other abbreviations as in Table 1.
Table 3. Influence of Era on Acceptance of O
of Older Donor Age on Early Post-Transplant
Era of
Transplantation
Donor Age
(yrs)
Donor
40 Ye
1992–1993 (n  122) 28.9  10.9 24 (2
1994–1996 (n  202) 33.4  13.7 64 (3
1997–1999 (n  155) 31.2  13.3 45 (2*Chi-square test. †Fisher test. Data are presented as the mean  Sortality was 2.5 times (95% confidence interval [CI] 1.25
o 5.12) greater in recipients of hearts from donors between
0 and 50 years old (p  0.01) and 4.3 times (95% CI 1.88
o 9.83) greater in recipients of hearts from donors 50
ears old (p  0.001). If patients who did not survive the
rst 30 days were excluded from the analysis, the long-term
urvival was no longer influenced by donor age, and the risk
f post-transplant mortality decreased to 0.78 (95% CI 0.44
o 1.48) for recipients of hearts from donors between 40 and
0 years old (p  0.39) and 1.51 (95% CI 0.73 to 3.14) for
ecipients of hearts from donors 50 years old (p  0.27).
As seen in Table 2, the multivariable Cox analysis
onfirmed that the risk of early post-operative mortality
ncreased with donor age and became an independent risk
actor for early post-operative death once donor age ex-
eeded 50 years (relative risk [RR] 2.8, p  0.02). Other
isk factors for early post-transplant mortality included
VA as the cause of the donor’s death (RR 3.7, p 0.006),
schemic time exceeding 4 h (RR 2.47, p  0.04), and the
ra of transplantation, with the RR of early post-transplant
ortality in years 1997 to 1999 decreasing from 2.7 in years
994 to 1996 (p 0.03) and from 5.1 in years 1992 to 1993
p  0.001). As illustrated in Table 3, the early mortality in
ecipients of hearts from donors 40 years old improved
hroughout the consecutive eras, and in years 1997 to 1999,
t was no longer significantly different from early mortality
n recipients of younger donor hearts. Recipient gender, age,
thnicity, diagnosis of heart disease, complete mismatch at
onor Hearts for Transplantation and Effect
rtality
Early Post-Transplant
Mortality (<30 days)
p Value
(log-rank)
Donor Age
<40 Years
Donor Age
>40 Years
9/98 (9%) 8/24 (33%) 0.002*
8/138 (6%) 10/64 (16%) 0.02*
2/110 (2%) 3/45 (7%) 0.12†
igure 1. Kaplan-Meier survival after heart transplantation by donor age.
verlapping squares (top) donor age40 years (n 346); triangles
onor age 40 to 50 years (n 97); circles donor age50 years (n 36).lder D
Mo
Age
ars
0%)
2%)
9%)D or number (%) of patients.
H
s
d
m
h
e
f
n
t
y
a
o
L
o

y
I
O
i
f
y
r
r
5
I
s
T
w
t
l
r
s
d
a
t
a
t
w
c
t
2
o
0
C
d
p
c
r
p
t
s
r
(
a
s
p
d
c
a
g
o
s
3
a
o
o
s
s
D
O
i
s
w
o
p
b
p
2
T
R
T
1557JACC Vol. 43, No. 9, 2004 Lietz et al.
May 5, 2004:1553–61 Outcomes of Cardiac Transplantation From Older DonorsLA-A, -B, and -DR loci, and pre-transplant LVAD
upport and re-transplantation were not associated with
ecreased post-operative survival.
The major causes of death within the first post-transplant
onth were sepsis (n  12), heart failure (n  11),
emorrhage (n  5), acute rejection (n  4), pulmonary
mbolism (n  2), ischemic stroke (n  2), multiorgan
ailure (n  1), and technical problems (n  2). There were
o statistically significant differences in the distribution of
he causes of death between recipients of hearts from donors
ounger and older than 40 years.
The use of pre-transplant mechanical support did not
ffect early mortality after transplantation in recipients of
lder donor hearts. Among 90 patients supported with
VAD before transplantation, early post-transplant death
ccurred in 2 (9%) of 22 recipients of hearts from donors
40 years old and 2 (3%) of 68 recipients of hearts from
ounger donors (p  0.24).
nfluence of donor age on high-grade acute rejection.
lder donor age (40 years) is not associated with an
ncreased risk of earlier acute rejection or an increased
requency of acute rejections within the first post-transplant
ear (Table 4). The incidences of at least one high-grade
ejection episode within the first post-operative year in
ecipients who received hearts from donors age 40, 40 to
0, and 50 years were 41%, 47%, and 36%, respectively.
nfluence of donor age on TCAD. A direct correlation is
een between increasing donor age and early development of
CAD. Based on the results of the first annual angiograms,
e have found that, when compared with donors younger
han 20 years, the third, fourth, and fifth decades of donor
ife increase the risk of TCAD by 2.2-, 2.4-, and 2.6-fold,
espectively (Table 5). As the risk of TCAD increases
tarting with the fourth decade of a donor’s life, Figure 2
emonstrates the relationship between donor age 30 years
nd time to the onset of TCAD (p 0.006). It is important
o note that the correlation between development of TCAD
able 5. Influence of Donor Age on Diagnosis of Transplant-
elated Coronary Artery Disease on First Annual Angiogram
Donor
Age (yrs)
Number (%) of
Patients With TCAD RR (95% CI) p Value
20 15/88 (17%) 1.0
20–30 21/81 (26%) 1.397 (0.642–3.042) 0.40
30–40 19/64 (30%) 2.213 (1.027–4.769) 0.04
40–50 23/67 (34%) 2.387 (1.143–4.984) 0.02
50 7/21 (34%) 2.643 (0.977–7.149) 0.05
Table 4. Influence of Donor Age on Acute Re
Heart Transplantation
Donor
Age (yrs)
Number (%) of
Rejectors RR (95% CI
40 132/329 (40%) 1.0
40–50 38/87 (44%) 1.083 (0.775–1.5
50 10/32 (31%) 0.806 (0.424–1.5
Abbreviations as in Table 2.ICAD  transplant-related coronary artery disease; other abbreviations as in Table 2.nd older donor age holds true only for the first post-
ransplant year (p  0.02), and when we exclude patients
ho developed TCAD within the first year, no significant
orrelation is found between one and five years after
ransplantation (p  0.16). The hazard function in Figure
A illustrates that the role of donor age in the development
f TCAD is confined to the first post-transplant year (p 
.01).
ardiac transplant waiting list mortality. Because older
onor hearts are associated with an increased risk of
ost-operative mortality, we compared mortality on the
ardiac transplant waiting list to the mortality for a recipient
eceiving a cardiac allograft from an older donor. For those
atients who underwent cardiac transplantation, survival on
he waiting list was tied to post-transplant survival. A
eparate analysis was performed for patients initially en-
olled in our institution as status I (n  352) and status II
n  534) on the UNOS waiting list between January 1992
nd January 1999.
Table 6 shows a comparison of statistical analysis of
ix-month mortality of status I and status II enrolled
atients who received a cardiac allograft from an older
onor (age 40 years) or younger donor (40 years), as
ompared with those patients who did not receive an
llograft. Figures 3A and 3B represent this correlation
raphically for status I and II patients, respectively. The risk
f death within six months from enrollment in status I and
tatus II patients who did not receive an allograft is 8.5- and
.7-fold, respectively, higher than in patients who received
n allograft. However, transplantation of a heart from an
lder donor (age 40 years) only slightly increases the risk
f six-month mortality to 1.6 for status I patients and 2.1 for
tatus II patients. This association does not reach statistical
ignificance.
ISCUSSION
ur experience supports previous findings of multi-
nstitutional (4,15) and single-center studies (16) of poorer
urvival in recipients of older donor hearts. The 346 patients
ho received a heart from donors 40 years old had a
ne-month mortality of 5%. In contrast, in 97 and 36
atients who received hearts from donors whose age was
etween 40 and 50 years and older than 50 years, the early
ost-operative mortality significantly increased to 13% (RR
.5, p  0.01) and 22% (RR 4.3, p  0.001), respectively.
n Episodes Within the First Year After
p Value
Cumulative Frequency
of Rejections p Value
0.55
0.66 0.73 0.11
0.51 0.41 0.32jectio
)
54)
34)nterestingly, our analyses show that the correlation be-
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Outcomes of Cardiac Transplantation From Older Donors May 5, 2004:1553–61ween older donor age and poor survival was confined to the
ery early perioperative period, and no further association
etween older donor age and survival was found beyond the
rst post-transplant month. The major causes of early
ost-transplant death in our population included sepsis,
eart failure, hemorrhage, and acute rejection, and their
istribution was similar between recipients of hearts from
ounger and older donors.
It is important to note that with the advances in patient
are in recent years, the early post-transplant outcomes at
ur center have significantly improved (20). In years 1997 to
999, the RR of one-month post-transplant mortality was
igure 2. Kaplan-Meier (A) freedom from transplant-related coronary
rtery disease (TCAD) and (B) hazard function for the presence of TCAD,
s detected by annual coronary angiography. Squares  donor age 30
ears (n  169); triangles  donor age 30 years (n  132).
Table 6. Comparison of Six-Month Mortality
Received a Transplant From an Older Donor (
Versus No Transplant
Mean Waiting
Time (months)
Status I
Donor 40 years old 2.6
Donor 40 years old 3.8
No donor 6.0
Status II
Donor 40 years old 7.6
Donor 40 years old 10.3
No donor 23.7Abbreviations as in Table 2..5 times lower than that in years 1994 to 1996 and five
imes lower than that in years 1992 to 1993. Parallel to these
hanges, the adverse influences of transplanting hearts from
lder donors also gradually diminished. The post-transplant
ortality rate in patients receiving hearts from donors older
han 40 years decreased from 33% in years 1992 to 1993 to
6% in years 1994 to 1996 and to 7% in years 1997 to 1999.
hese eras represent important milestones in the care of
atus I and Status II Enrolled Patients Who
Years) or Younger Donor (40 Years)
ber (%)
eaths RR (95% CI) p Value
5 (14%) 1.0 —
2 (21%) 1.626 (0.793–3.336) 0.18
5 (70%) 8.542 (5.734–12.725)  0.001
6 (6%) 1.0 —
0 (12%) 2.063 (0.830–5.129) 0.12
8 (24%) 3.667 (2.197–6.120)  0.001
igure 3. Kaplan-Meier survival from enrollment on waiting lists for (A)
tatus I and (B) status II patients.of St
40
Num
of D
23/16
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95/13
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May 5, 2004:1553–61 Outcomes of Cardiac Transplantation From Older Donorseart recipients at our center. In 1994, azathioprine in the
riple immunosuppressive regimen was replaced by myco-
henolate mofetil, which has been previously described to
orrelate with improved survival in heart transplant recipi-
nts (21). Also, since 1996, the bicaval anastomosis tech-
ique was introduced to perform heart transplantation,
nstead of the previously used biatrial technique. Although
ther authors did not find bicaval anastomosis to be superior
o older techniques in terms of graft survival (22), it is one
f the many factors that could have contributed to improved
eri-operative outcomes at our center.
Because the risk for death in patients who received hearts
rom older donors was greatest in the early post-transplant
eriod, we investigated whether other factors that might
ffect the quality of the transplanted heart may correlate
ith a poor survival. Both the ISHLT registry data (4) and
ther independent investigators (14–16) have suggested
hat an ischemic time 4 h may increase the risk for death
n recipients who receive hearts from donors older than 50
ears. Our analysis revealed that ischemic time 4 h and
onor death resulting from CVA significantly contributed
o poor early post-transplant outcomes and outweighed the
mportance of recipient demographics and mechanical sup-
ort before transplantation.
The association between TCAD and donor age is con-
roversial. Some authors found no significant association
etween older donor age and accelerated TCAD (12,23,24),
n contrast to a multi-institutional study (25). Gao et al. (23)
howed that despite a higher incidence of moderate to
evere intimal thickening, as detected by intravascular ultra-
ound in older donors, older donor age was not significantly
ssociated with the subsequent development of TCAD.
owever, these authors state that knowledge of the extent
o which advanced intimal thickening in older donor hearts
s associated with a higher incidence of late TCAD on
ngiograms was limited by the small number of patients and
hort follow-up duration in this study. In this study, we
emonstrate that the risk of TCAD increases with every
ecade of donor age (Table 6). By the end of the first
ost-transplant year, 17% of recipients of hearts from young
onors (20 years old) develop angiographic evidence of
CAD, compared with 26% of recipients of hearts from
onors in their third decade, 30% of recipients of hearts
rom donors in their fourth decade, 34% of recipients of
earts from donors in their fifth decade, and 34% of
ecipients from donors 50 years old. As shown in Table 5,
he donor’s cutoff age at which the risk of TCAD starts to
ncrease is 30 years (Fig. 3A). Interestingly, as the hazard
unction shows in Figure 3B, the risk of TCAD develop-
ent is confined to the first post-transplant year and
ubsides thereafter. It is possible that the correlation be-
ween the donor age and incidence of TCAD limited to the
rst post-transplant annual angiogram may reflect the pres-
nce of pre-existing CAD in a donated heart, and not true
evelopment of transplant vasculopathy. Several previous
tudies showed that the use of older donor hearts was hssociated with preexisting CAD present before the donor’s
eath (26). Although our center generally does not accept
earts from female donors 45 years old and male donors
40 years old with angiographic evidence of CAD in more
han one major vessel, subtle pre-transplant lesions could
ead to the post-transplant findings interpreted as transplant
asculopathy. Unfortunately, the majority of the donor
oronary angiograms were obtained in other hospital cen-
ers, and we were not able to compare them with the first
nnual post-transplant angiograms taken in recipients.
Because frequent episodes of acute rejection may accel-
rate the development of TCAD (27), we investigated
hether recipients of older donor hearts exhibit a higher
lloreactivity to the donor allograft. However, no correlation
as found between donor age and either the time to the first
igh-grade acute rejection or the annual cumulative rejec-
ion frequency. Ventura et al. (28) suggested that vessels
rom older hearts may be more susceptible to damage caused
y rejection, and that multiple rejection episodes in recipi-
nts of older donor hearts may even further accelerate the
evelopment of allograft vasculopathy. Although similar
rends were observed in our current series, no statistically
ignificant associations were found.
The higher mortality for patients receiving hearts from
lder donors has raised questions regarding the criteria for
onor selection. Is it worth transplanting hearts from older
onors? It is clear that the upper limit of donor age has
teadily increased over the past three decades. Rodeheffer et
l. (29) reported a maximum donor age of 34 years among
,749 heart transplant recipients in a multi-institutional
tudy between 1990 and 1994. In contrast, of the 479 heart
ransplantations performed at our center, 133 (28%) were
btained from donors older than 40 years. In our experience,
he mean age of heart donors varied depending on the
roportion of hearts harvested from donors 40 years old
nd rose from 29 years old between 1992 to 1993 to 33 years
etween 1994 and 1996, with a slight decline to 31 years
rom 1997 to 1999.
It is important to keep in mind that patients with
nd-stage heart failure face a significant risk of death while
waiting heart transplantation. The UNOS registry data
eveal that patients with blood group O have a median
aiting time of 332 days; the median waiting time for
atients18 years old was 230 days (30). Bennett et al. (31)
howed that despite an initial risk resulting from the
ransplant procedure, there was a clear long-term survival
enefit for status I recipients who received older donor
earts. Their analysis revealed that 30 days after transplan-
ation, the risk of death for recipients of 45- to 49-year-old
onor hearts was lower than that if they remained on the
aiting list, and at six months, the RR was 0.37. Further,
or recipients of hearts from donors 50 years or older, the
isk after transplantation was lower after 64 days, and by six
onths, the RR was 0.48. Our results support these
mportant findings. Although recipients of older donor
earts had poorer early survival than did recipients of hearts
f
b
o
s
7
s
y
p
d
c
h
r
2
w
c
y
e
t
s
t
i
t
e
c
h
o
s
t
n
p
s
p
i
i
o
i
r
i
t
d
i
d
t
w
o
S
a
p
s
t
f
e
d
l
a
a
w
T
c
c
C
p
n
t
d
i
m
s
i
t
n
b
w
l
a
r
n
n
t
d
P
b
R
o
t
A
R
1560 Lietz et al. JACC Vol. 43, No. 9, 2004
Outcomes of Cardiac Transplantation From Older Donors May 5, 2004:1553–61rom donors younger than 40 years, it was still much more
eneficial to transplant an older donor heart than to remain
n the waiting list, particularly for status I patients. For
tatus I patients, six-month mortality on a waiting list was
0%, and the risk of death was 8.5 times higher than that of
tatus I patients who received an allograft from donors 40
ears old, with a resulting 14% six-month mortality. Trans-
lantation of an older donor heart increased the risk of
eath in those recipients to 1.6 times but was not statisti-
ally significantly different from recipients who received
earts from donors 40 years old. Similarly, in status II
ecipients, those not transplanted had a mortality rate of
4% within the first six months from enrollment on a
aiting list. This increased the risk of death 3.7 times, as
ompared with status II patients receiving a heart from a
ounger donor (40 years old). Although status II recipi-
nts of older donor (40 years old) hearts slightly increased
he risk of death to twofold, this difference did not reach
tatistical significance. Thus, it is reasonable to conclude
hat expansion of donor age to 40 years is more beneficial,
n terms of a risk/benefit ratio, than indefinitely waiting on
he transplant list (32). These benefits may be even more
vident in unstable UNOS status I patients who are criti-
ally ill and who appear to be deteriorating despite maximal
emodynamic support. The data we provide support the use
f donors even older than 50 years in status I patients, as
ix-month survival is better, compared with remaining on
he transplant waiting list. As UNOS status II patients do
ot have a dramatic survival improvement when trans-
lanted with older donor hearts, as compared with UNOS
tatus I patients, it would be advisable to consider trans-
lantation of older donor hearts only to status I patients. It
s important to note that the use of ventricular assist devices
n status I patients may obviate the need to urgently use an
lder donor heart. However, if an older donor heart is used,
t is important to avoid or at least minimize other known
isk factors that adversely affect survival, such as a prolonged
schemic time. Further, clinical hemodynamic stability of
he recipient would also improve the chances of the older
onor cardiac allograft to function satisfactorily. In addition,
t remains imperative that a more aggressive approach to
etection of TCAD, as well as the development of therapies
o treat TCAD in recipients of older donor allografts, is
arranted in light of our findings of an increased prevalence
f TCAD in these recipients.
tudy limitations. This study includes those limitations
ssociated with a retrospectively performed study. It is also
ossible that older donor hearts were transplanted into
icker recipients who had a higher probability of death if
hey remained on the waiting list. This does not detract
rom our study conclusions, but only offers an additional
xplanation for the poorer survival in recipients of older
onor hearts. Unlike several studies focusing on this prob-
em, ours did not suffer from the lack of standardization
ssociated with multicenter studies. We were also unable to
nalyze the UNOS status at the time of transplantation, ase were unable to obtain complete data on this variable.
his is important, as the UNOS listing often changes as the
linical condition of patients with end-stage heart failure
hanges.
onclusions. The risk of early mortality after heart trans-
lantation from donors older than 40 years is increased
early threefold and is multifactorial in nature. Although
he absolute risk of early mortality in recipients of older
onor hearts has decreased over the advancing eras of
nstitutional experience, the proportional increase of early
ortality with the use of older donor hearts remained the
ame. The use of older donors is associated with an increase
n the incidence of TCAD at one year. There is evidence in
he literature to suggest that this increase may be due to
ative CAD in the donor. Angiograms should be reviewed
y the recipient’s institution to rule out noncritical CAD,
hich might worsen after transplantation due to immuno-
ogic stimulation or an increase in traditional risk factors
fter transplantation. If angiograms cannot be reviewed,
ecipients of older donor heart should undergo early coro-
ary angiography to evaluate native atherosclerosis. There is
o survival advantage for status II patients awaiting a heart
ransplant to receive older donor hearts; therefore, older
onors should be used for critically ill status I patients.
atients most likely to die should be identified, allowing
etter utilization of devices or transplant organs.
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